Clinical and Computational Support

临床和计算支持

• 批准号: 8336789
• 负责人: Hanne M Kooy
• 金额: $ 3.14万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-21 至 2014-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8336789
• 关键词: Cancer Center; Clinical; Clinical Trials; Dose; Enrollment; Equipment; Evaluation; General Hospitals; Image; Immobilization; Maintenance; Massachusetts; Measurement; Methods; Nature; Non-Small-Cell Lung Carcinoma; Patients; Play; Process; Proton Radiation; Protons; Radiation therapy; Research; Research Infrastructure; Role; Services; Site; Speed; System; Techniques; Text; Therapeutic Studies; University of Texas M D Anderson Cancer Center; design; dosimetry; image processing; in vivo; parallel processing; quality assurance; respiratory; treatment planning; treatment site; verification and validation

The role of Core B is to provide the following services: (1) support for treatment planning, (2) quality assurance and delivery of treatments for patients enrolled in the clinical trials of Projects 1 and 2, (3) Monte Carlo computations and management of high-speed parallel processing system for all four projects, and (4) measurements in phantom for experimental verification and validation of computed dose distributions for all four projects. This core will also play a significant role in the implementation of new methods resulting from research in Projects 1 through 4. Examples include image-guided setup, respiratory-gating, new plan evaluation techniques, in vivo dosimetry, reduced margins, adaptive replanning and intensity modulated proton therapy. For Project 1 (non-small cell lung cancers) and Project 2 (other challenging sites) treatment site-specific support will be provided for 1) immobilization, imaging (including repeat imaging and 4D imaging) and treatment set up; (2) planning of PSPT and IMPT, incorporation of results of research into treatment plan design and evaluation strategies and maintenance of proton treatment planning infrastructure; (3) quality assurance of new planning and treatment techniques prior to their clinical implementation; (4) patient specific dosimetric quality assurance; (5) image-guided setup and respiratory-gating; and (6) in-vivo dosimetry. The high-speed parallel CPU cluster system will be used for Monte Carlo calculations, optimization and image processing for all four projects. Because of the differences in equipment, systems and processes between MGH and MDACC, Core B has been divided into two parts. Core B1 will support MGH activities whereas Core B2 will support the MDACC activities

核心B的作用是提供以下服务：（1）支持治疗计划，（2）质量 为参加项目1和2临床试验的患者提供治疗保证和服务，（3）Monte 所有四个项目的卡洛计算和高速并行处理系统的管理，以及（4） 体模中的测量，用于实验验证和确认所有 四个项目。 这一核心还将在实施研究所产生的新方法方面发挥重要作用， 项目1至4。示例包括图像引导设置、自动门控、新计划评估 技术，在体内剂量测定，减少利润，适应性重新规划和强度调制质子治疗。 对于项目1（非小细胞肺癌）和项目2（其他挑战性部位），治疗部位特异性 将为1）固定、成像（包括重复成像和4D成像）和 治疗设置;（2）计划PSPT和IMPT，将研究结果纳入治疗计划 质子治疗计划基础设施的设计和评估策略以及维护;（3）质量 在临床实施之前确保新的规划和治疗技术;（4）患者特异性 剂量测定质量保证;（5）图像引导设置和放射性门控;和（6）体内剂量测定。 高速并行CPU集群系统将用于蒙特卡罗计算、优化和 四个项目的图像处理。 由于MGH和MDACC在设备、系统和工艺上的差异，核心B 被分为两部分。核心B1将支持MGH活动，而核心B2将支持MDACC 活动